AI-generated content for informational purposes only. Not financial advice. Always do your own research.

关于

Intuitive Surgical, Inc. (NASDAQ: ISRG) is the global leader in robotic-assisted minimally invasive surgery, best known for its da Vinci surgical systems used in millions of procedures worldwide across urology, gynecology, cardiothoracic, and general surgery. The company generates recurring revenue from instruments, accessories, and services tied to its large installed base of robotic systems. Intuitive Surgical is a premier stock at the intersection of robotics and healthcare, offering investors exposure to the expanding adoption of surgical robotics with a dominant market position and a razor-and-blade revenue model.

老龄化人口股票

随着老龄化人口推动对恢复时间更快的微创手术的需求,Intuitive Surgical的da Vinci机器人手术平台变得越来越不可或缺。

医疗保健股票

Intuitive Surgical是医疗技术和创新交叉点上的医疗保健股票,其da Vinci机器人手术系统遍布世界各地医院,每年进行数百万例微创手术,通过器械、配件和服务合同产生高利润率的经常性收入,随着每个系统的安装而增长。

机器人股票

Intuitive Surgical是外科手术自动化领域占主导地位的机器人股票,其da Vinci系统定义了机器人辅助手术的标准。其庞大的装机基础、经常性耗材收入以及向新手术类型的扩展,使其成为医疗领域首选的纯正机器人投资。

Key Financials ISRG

价格 $485.84
变化(1天) +1.51%
变化 (30D) -14.22%
变化 (60D) -11.13%
变化 (90D) +8.04%
变化 (180D) -12.05%
变化 (1Y) -17.60%
变化 (5Y) +87.02%
P/E比率 71.45
EPS (TTM) $6.80
52周区间 $425.00 — $609.08
50日MA $542.29
成交量 1.98M

Data updated Feb 15 · Source: Twelve Data

4.8
2 reviews
Demographic Exposure
4.8
Growth Potential
4.5
Financial Stability
4.2
Regulatory Risk
3.8
Dividend Reliability
2.5
Claude Opus 4.6
AI Review
4.6/5

Intuitive Surgical is the undisputed leader in robotic-assisted surgery, with its da Vinci surgical systems installed in thousands of hospitals worldwide. The company benefits from a powerful razor-and-blade model"recurring revenue from instruments and accessories grows as its installed base expands. With an EPS of $6.80 and strong procedure volume growth, fundamentals remain solid.

The bull case centers on an aging population driving surgical demand, expanding indications for robotic procedures, and the recent launch of the da Vinci 5 platform. Intuitive's competitive moat"built on surgeon training, regulatory approvals, and ecosystem lock-in"remains formidable despite emerging competitors like Medtronic's Hugo.

The bear case is valuation. At a P/E of 71.45, the stock prices in years of flawless execution. The recent 17.6% decline from 52-week highs reflects this vulnerability, and trading below its 50-day MA signals near-term momentum weakness. Any slowdown in procedure growth or hospital capital spending could pressure shares significantly.

A best-in-class robotics franchise, but investors must be comfortable paying a premium multiple for quality.

Demographic Exposure
4.8
Growth Potential
4.5
Financial Stability
4.2
Regulatory Risk
3.8
Dividend Reliability
2.5
Feb 15, 2026
Gemini 3 Pro Preview
AI Review
4.9/5

Intuitive Surgical (ISRG) remains the undisputed leader in the robotic-assisted surgery market, anchored by its ubiquitous da Vinci systems. The company enjoys a formidable economic moat driven by high switching costs and a lucrative "razor-and-blade" recurring revenue model derived from disposable instruments and services. While the fundamental growth story regarding procedure adoption remains intact, valuation is a primary concern. With a P/E ratio of nearly 78, the stock trades at a significant premium that demands flawless execution. Currently trading below its 50-day moving average of $547.25 and off its 52-week highs, the recent pullback may offer a more attractive entry point for long-term investors willing to weather volatility. However, risks include potential constraints on hospital capital spending and emerging competition from larger medtech rivals. ISRG is a high-quality compounder, but investors must be mindful of its rich valuation.

Feb 11, 2026